Ipilimumab
About
Therapy type: Immunotherapy
Therapy strategy: CTLA-4 inhibition
Mappings
NCI Thesaurus: Ipilimumab (ncit:C2654)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (2) | MSI-H | Colorectal Adenocarcinoma | Ipilimumab, Nivolumab | |
| FDA (1) HC (2) | PD-L1 >= 1%, Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Ipilimumab, Nivolumab | |
| FDA (2) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Carboplatin, Ipilimumab, Nivolumab, Pemetrexed | |
| FDA (2) HC (1) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Cisplatin, Ipilimumab, Nivolumab, Pemetrexed | |
| FDA (2) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Carboplatin, Ipilimumab, Nivolumab, Paclitaxel | |
| FDA (1) | PD-L1 >= 1% | Non-Small Cell Lung Cancer | Ipilimumab, Nivolumab | |
| FDA (2) | dMMR | Colorectal Adenocarcinoma | Ipilimumab, Nivolumab | |
| HC (2) | PD-L1 >= 1% | Esophageal Squamous Cell Carcinoma | Ipilimumab, Nivolumab |